Deuremidevir for COVID-19: real-time meta-analysis of 2 studies

Significantly lower risk is seen for recovery and viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit.

Meta-analysis using the most serious outcome reported shows 11% [-1‑21%] lower risk, without reaching statistical significance. Results are better for Randomized Controlled Trials.

Control Deuremidevir

Currently there is limited data, with only 1 control event for the most serious outcome in trials to date. Studies to date are from only 2 different groups.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

Zheng et al. present another meta-analysis for deuremidevir, showing significant improvement for viral clearance.